The 2026 Oral Probiotic and Topical Secretome Acne Trial Protocol: Product-Claim Questions for Adults With Persistent Acne

The 2026 phase 2 protocol tests oral probiotics and a topical secretome as add-ons to standard therapy in four groups over 8 weeks. For adults with persistent acne, it provides a test plan, not proof that either product improves adult breakouts. Secretome means the mix of signals cells release, here made into a skin serum.

Persistent acne means adolescent acne that continues past age 25. Every group also uses nightly clindamycin-plus-tretinoin cream, so the trial measures extra benefit. The document is a protocol only and reports no efficacy or safety results.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

What does the trial test?
Who fits the study definition?
What are the two add-on products?
What is measured after 8 weeks?
How should adults judge product claims now?

What does the trial test?

BMJ Open published the protocol on 4 June 2026 as a double-blind randomized phase 2 study the published protocol. It runs four parallel arms over 8 weeks. The design compares combinations with oral probiotic and topical secretome. No arm tests probiotic or secretome alone.

BMJ Open states every participant also applies clindamycin-plus-tretinoin cream to acne areas each night. The question is adjunctive benefit on top of standard therapy. The outcomes use pretest-posttest comparison. That structure shows change from baseline rather than long-term control.

Who fits the study definition?

The trial enrolls dermatologist-diagnosed mild-to-moderate facial acne vulgaris. BMJ Open defines severity by Lehmann lesion counts. It does not enroll severe or nodular disease alone.

For context, MDedge/Clinician Reviews reporting dermatology experts described adult female prevalence at 15-20%, with about 80% of adult cases persistent in one clinical summary. Persistent cases are continuations from adolescence into age 25 and older. Readers can use that definition as a quick check:.

diagnosis is facial acne vulgaris by a dermatologist
severity is mild to moderate by lesion count
current disease continues from teenage years into adulthood
severe nodular disease alone does not match the protocol group

What are the two add-on products?

The oral product is HEXBIO granules taken twice daily after meals for 8 weeks. The ICH GCP registry mirror for NCT06925386 lists six strains the registry entry. They are Lactobacillus acidophilus BCMC 12130, L. casei 12313, L. lactis 12451, Bifidobacterium bifidum 02290, B. longum 02120 and B.

infantis 02129. The topical product is a hydrogel serum. BMJ Open describes secretome components including cytokines, growth factors, exosomes, microvesicles and differentiation factors. The base contains xanthan/sclerotium gum, alginate, glycerin, caprylyl glycol and water. Dose timing matters for interpretation. Twice-daily granules after meals and daily serum use set a fixed 8-week exposure. A missed dose or shorter course would not match the tested plan.

What is measured after 8 weeks?

BMJ Open lists acne severity and lesion measures before and after treatment. The same window includes fecal microbiome testing. Related clinical restoration endpoints are also recorded. That pairing links skin change with gut-microbiome change.

It does not establish that microbiome change causes skin improvement. It only allows researchers to compare both shifts over the same period. PubMed records the June 2026 document as a protocol. A protocol describes methods and planned endpoints before results exist.

How should adults judge product claims now?

A protocol without results cannot support a claim that HEXBIO or this secretome serum clears persistent adult acne. Advertising for disease treatment needs stronger support. The Federal Trade Commission requires competent and reliable scientific evidence, generally human randomized controlled testing, before advertising disease treatment the FTC health-claim principles. The Food and Drug Administration treats cosmetics claiming to mitigate acne as drugs requiring review, as reported by FDA via Healio the FDA consumer warning.

A cosmetic label is not the same as drug review. Disease language such as treats, clears, or cures acne raises that line. Adults considering either product can ask a dermatologist whether continued clindamycin-plus-tretinoin remains appropriate and whether to wait for completed results. Bring the product label and current prescription list to that visit.